Dashboard
1
Poor Management Efficiency with a low ROCE of 6.26%
- The company has been able to generate a Return on Capital Employed (avg) of 6.26% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -2.30% and Operating profit at 12.14% over the last 5 years
3
Negative results in Mar 25
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,020 Million (Small Cap)
15.00
NA
0.00%
-0.40
5.07%
0.77
Revenue and Profits:
Net Sales:
179 Million
(Quarterly Results - Jun 2025)
Net Profit:
29 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.52%
0%
-9.52%
6 Months
-6.74%
0%
-6.74%
1 Year
1.82%
0%
1.82%
2 Years
-3.74%
0%
-3.74%
3 Years
-6.76%
0%
-6.76%
4 Years
-49.64%
0%
-49.64%
5 Years
0%
0%
0.0%
Zhejiang Benli Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.30%
EBIT Growth (5y)
12.14%
EBIT to Interest (avg)
44.01
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
0.51
Tax Ratio
14.19%
Dividend Payout Ratio
32.18%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.26%
ROE (avg)
4.68%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
0.77
EV to EBIT
8.76
EV to EBITDA
4.24
EV to Capital Employed
0.61
EV to Sales
0.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.02%
ROE (Latest)
5.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
178.70
189.20
-5.55%
Operating Profit (PBDIT) excl Other Income
45.30
36.70
23.43%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
29.40
24.90
18.07%
Operating Profit Margin (Excl OI)
167.30%
118.50%
4.88%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -5.55% vs 10.64% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 18.07% vs 36.81% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
703.60
691.80
1.71%
Operating Profit (PBDIT) excl Other Income
112.20
100.60
11.53%
Interest
0.30
0.90
-66.67%
Exceptional Items
0.50
0.00
Consolidate Net Profit
64.60
59.60
8.39%
Operating Profit Margin (Excl OI)
77.50%
67.90%
0.96%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.71% vs -8.42% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 8.39% vs -0.33% in Dec 2023
About Zhejiang Benli Technology Co., Ltd. 
Zhejiang Benli Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






